Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT04576455 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04576455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04576455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 27, 2020
Completion date
August 25, 2027
Enrollment
303 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive, her2-negative, locally advanced or metastatic breast cancer